191 related articles for article (PubMed ID: 19435959)
1. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Pruski M; Krysiak R; Okopien B
Diabetes Care; 2009 Aug; 32(8):1421-4. PubMed ID: 19435959
[TBL] [Abstract][Full Text] [Related]
2. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
Krysiak R; Gdula-Dymek A; Okopien B
Am J Cardiol; 2011 Apr; 107(7):1010-1018.e1. PubMed ID: 21276586
[TBL] [Abstract][Full Text] [Related]
3. Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance.
Krysiak R; Gdula-Dymek A; Okopień B
Pharmacol Rep; 2013; 65(5):1311-6. PubMed ID: 24399727
[TBL] [Abstract][Full Text] [Related]
4. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
Okopień B; Krysiak R; Herman ZS
J Clin Endocrinol Metab; 2006 May; 91(5):1770-8. PubMed ID: 16492702
[TBL] [Abstract][Full Text] [Related]
5. Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose.
Krysiak R; Handzlik G; Okopień B
Pharmacol Rep; 2010; 62(6):1099-107. PubMed ID: 21273667
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
7. The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Krysiak R; Gdula-Dymek A; Marek B; Okopień B
Endokrynol Pol; 2016; 67(2):190-6. PubMed ID: 26884290
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Krysiak R; Gdula-Dymek A; Marek B; Okopień B
Endokrynol Pol; 2015; 66(3):224-30. PubMed ID: 26136131
[TBL] [Abstract][Full Text] [Related]
9. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
10. Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
Krysiak R; Gdula-Dymek A; Okopień B
Pharmacol Rep; 2013; 65(1):208-13. PubMed ID: 23563040
[TBL] [Abstract][Full Text] [Related]
11. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.
Grant PJ
Diabetes Care; 1996 Jan; 19(1):64-6. PubMed ID: 8720537
[TBL] [Abstract][Full Text] [Related]
12. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Linz PE; Lovato LC; Byington RP; O'Connor PJ; Leiter LA; Weiss D; Force RW; Crouse JR; Ismail-Beigi F; Simmons DL; Papademetriou V; Ginsberg HN; Elam MB
Diabetes Care; 2014; 37(3):686-93. PubMed ID: 24296848
[TBL] [Abstract][Full Text] [Related]
14. Summarizing the FIELD study: lessons from a 'negative' trial.
Tsimihodimos V; Mikhailidis DP; Elisaf M
Expert Opin Pharmacother; 2013 Dec; 14(18):2601-10. PubMed ID: 24206060
[TBL] [Abstract][Full Text] [Related]
15. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Krysiak R; Okrzesik J; Szkrobka W; Okopień B
Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.
Krysiak R; Stachura-Kułach A; Okopień B
Pharmacol Rep; 2010; 62(1):120-30. PubMed ID: 20360622
[TBL] [Abstract][Full Text] [Related]
17. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
18. Effects of medical therapies on retinopathy progression in type 2 diabetes.
; ; Chew EY; Ambrosius WT; Davis MD; Danis RP; Gangaputra S; Greven CM; Hubbard L; Esser BA; Lovato JF; Perdue LH; Goff DC; Cushman WC; Ginsberg HN; Elam MB; Genuth S; Gerstein HC; Schubart U; Fine LJ
N Engl J Med; 2010 Jul; 363(3):233-44. PubMed ID: 20587587
[TBL] [Abstract][Full Text] [Related]
19. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
Okopien B; Cwalina L; Lebek M; Kowalski J; Zielinski M; Wisniewska-Wanat M; Kalina Z; Herman ZS
Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
[TBL] [Abstract][Full Text] [Related]
20. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
